USA), is miscible in water and forms a microemulsion lel-group, multicenter prospective study of stable maintenance in the gut. The Neoral formulation has a bioavailability renal transplant patients to compare the safety and tolerability that is approximately 30% greater than that of Sandimof converting from Sandimmune to Neoral (N ϭ 132) versus mune and, perhaps more importantly, is absorbed much continuing Sandimmune (N ϭ 130). Patients were studied for one year. The cyclosporine (CsA) dose was adjusted as necesmore consistently within an individual [4] [5] [6] [7] [8] [9] . Additionsary to maintain site-specific trough whole blood levels.
ally, there is less effect of food, particularly fatty food,
Results. During the study, dose adjustments were frequent on absorption and blood levels of CsA, which makes in both groups: 67% Neoral versus 65% Sandimmune patients.
administration and monitoring more convenient [10, 11] .
At study completion, the mean trough CsA levels were compaDespite the improved pharmacokinetic characteristics rable; the dose change-from-baseline did not differ statistically between groups. Fewer Neoral (87.1%) than Sandimmune of Neoral, some centers have encountered difficulty with (95.4%) patients reported adverse events, and serious adverse the conversion of some patients from Sandimmune to events were comparable. Adverse events related to CsA were Neoral and have reported precipitation of toxicity and not more common in the Neoral group. Renal function mearejection [12, 13] . Other investigators, however, have sures also implied comparability of the two treatments. Three Neoral versus five Sandimmune patients experienced acute found that individualized dose adjustments can ameliorejection; two Neoral versus five Sandimmune patients experirate toxicity without increasing the risk of rejection enced chronic graft dysfunction. Two septic deaths occurred [14] [15] [16] [17] [18] [19] to Neoral [19] imply that individualized monitoring after conversion is important. In that study, patients were converted to Neoral on a mg-for-mg dose basis and the The benefits of immunosuppression with cyclosporine dose titrated, as necessary, to re-establish each patient's (CsA) can be accompanied by troublesome adverse efprestudy trough level. More patients who received Sandfects, including nephrotoxicity, hypertension, and neuroimmune at a dose Ն4.0 mg/kg/day required a dose reductoxicity [1, 2] . The lipophilic molecular structure and tion, compared with those whose Sandimmune dose was resulting insolubility of the Sandimmune formulation of Յ4.0 mg/kg/day (98.6% vs. 79.6%, respectively). A recent open-label, multicenter study in Canada has demonstrated the safety and efficacy of conversion in chemistry screening (serum creatinine, blood urea nitrogen, serum calcium, phosphorous, sodium chloride, potassium, bicarbonate, alanine transaminase, aspartate neous U.S. population of maintenance renal transplant transaminase, magnesium, alkaline phosphatase, albupatients is unclear. This article reports a randomized, min, cholesterol, triglycerides, glucose, and uric acid). double-blind, multicenter U.S. study comparing the safety and tolerability of Neoral to that of Sandimmune.
Glomerular filtration rate evaluations and pharmacokinetic profiling
An assessment of GFR was performed at one center METHODS on a subset of 28 patients at weeks Ϫ1, 4, 24, and 52 Study design and primary objective using the Renalyzer iohexol method. Results from the The study was a double-blind, parallel-group, randompharmacokinetic profiling, which was undertaken on a ized, 19-center study of the safety and tolerability of further subset of patients at two other centers, have been the conversion of maintenance renal transplant patients reported elsewhere [20] and will not be delineated in from Sandimmune to Neoral with one year of follow-up. this article. Patients administered Sandimmune soft gel caps twice daily were randomized either to continue on SandimStatistics mune (N ϭ 130) or to convert to Neoral soft gel caps Data analyses were carried out using PC SAS (version (N ϭ 132) twice daily. Pharmacokinetic profiles were 6.12; SAS Institute, Cary, NC, USA). Differences in carried out on a subset of patients at two centers, and characteristics and outcomes of patients were tested usthe glomerular filtration rate (GFR) evaluations were ing Fisher's exact test (two-tailed) for categorical variperformed on a second subset of patients at a third ables, and, for continuous variables, either the Wilcoxon center.
rank sums test or, for demographic variables, analysis of variance. Differences with probabilities Յ 0.05 were Study population, randomization, and considered significant. For descriptive purposes, quantitastudy medication tive variables are typically reported using the mean (Ϯsd). The key inclusion and exclusion criteria are detailed in Table 1 . Study medications, provided by Novartis Pharmaceuticals Corporation, were identical in appear-RESULTS ance and odor. Dosing of the study medication was adBaseline demographic characteristics justed to maintain center-specific target CsA whole blood Baseline demographic characteristics were comparatrough levels. CsA blood levels were determined by a ble for the two groups and were representative of the central laboratory (Clinical Reference Laboratory, Lengeneral population of renal transplant recipients in the exa, KS, USA) using the Abbot monoclonal TDx assay.
United States (Table 2 ). Overall, the mean age at ranBlood levels were measured at the following times during domization was 42.6 years. Fifty-five percent were male, the study: weeks Ϫ2, Ϫ1, days 0 (day of conversion) and and 74% were white. The mean time from transplanta-3, weeks 1 and 2, months 1, 2, 3, 4, 5, 6, and 9, and at the study completion.
tion to conversion was 40.4 months. The frequency distri- At study completion, the dose of CsA relative to baseline for the Neoral group was higher in 7 (5.7%), lower bution of the time since transplantation for each group in 65 (53.3%), and unchanged in 50 (41.0%) patients, is shown in Figure 1 . Diabetes was the most common whereas the mean daily dose decreased by 38.5 mg (0.52 specific cause of end-stage renal disease, occurring in mg/kg). For the Sandimmune group, the dose at study 26% of randomized patients. Seventy-eight percent of completion was higher in 14 (11.5%), lower in 52 the patients were recipients of a cadaveric renal allograft.
(42.6%), and unchanged in 56 (45.9%) patients, whereas the mean dose decreased by 26.4 mg (0.36 mg/kg). The At randomization, 30% of the Neoral patients and 28% differences in the change from baseline between the two of the Sandimmune patients were insulin-dependent diatreatment groups failed to attain statistical significance betics, and 88% in each group were hypertensive; the (P ϭ 0.07). At study completion, the means of the trough mean serum creatinine for each group was 1.6 mg/dl.
CsA levels for the two groups were also comparable: 194 Ϯ 71 ng/dl in the Neoral patients versus 189 Ϯ 67 Discontinuations ng/dl in the Sandimmune patients, and the change from Eighteen patients (10 Neoral and 8 Sandimmune) disbaseline was comparable for the two groups. Because the continued. The discontinuations related to AEs were as weights of these maintenance-phase patients remained follows: for the Neoral group, death (N ϭ 2), rejection essentially stable throughout the study [mean (sd) (2), cerebrovascular accident (1), and increased liver enchange from baseline was Ϫ0.1 (Ϯ4.9) and Ϫ0.3 (Ϯ5.4) zymes (1); and for the Sandimmune group, the AEs were kg for the Neoral and Sandimmune groups, respectively], acute rejection (2), transplant nephropathy (1), and an changes in CsA dose during the study would not be unspecified AE (1) .
meaningfully affected if the dose were expressed as mg/kg.
Patient and graft survival Adverse events Two patients in the Neoral group died of sepsis during
Adverse events were reported in fewer patients ranthe course of the study. One had been hospitalized with domized to receive Neoral (115/132, 87.1%) versus Sansymptoms of infection since week 2 of the study and had dimmune (124/130, 95.4%, P ϭ 0.03). There were no received study medication for 102 days at the time of statistically significant differences between the groups in death. The second patient developed a rapidly progresreported AEs for any specific body system. Interestingly, sive systemic infection after receiving study medication there were also no significant differences in AEs that for 200 days. In the opinion of the investigators, the are known to be CsA related (Table 3 ). This observation is important because the higher CsA exposure afforded death of the first patient was possibly related to the by the Neoral formulation might have been thought to Glomerular filtration rate and serum creatinine levels be associated with an increase in such AEs.
At baseline, the mean GFRs were 47.9 Ϯ 16.9 ml/min/ There were no significant differences between the 1.73 m 2 versus 51.6 Ϯ 15.7 ml/min/1.73 m 2 in Neoral and groups in the numbers of patients experiencing serious Sandimmune patients, respectively. The changes from AEs. Infections occurred in 12 (9.0%) patients randombaseline over the course of the study were not statistically ized to Neoral and in 7 (5.4%) patients randomized to significant. At study completion, the mean GFR in the Sandimmune. Malignancy occurred in 10 (3.8%) patients two groups had decreased by 2.5% (46.7 Ϯ 22.0 ml/min/ overall; renal cell carcinoma occurred in one patient 1.73 m 2 ) for the Neoral patients versus 2.3% (50.4 Ϯ 14.8 receiving Neoral, and squamous cell carcinoma occurred ml/min/1.73 m 2 ) for the Sandimmune patients. in two patients who received Neoral and four patients Throughout the study, renal function, as assessed by who received Sandimmune. Basal cell carcinoma ocserum creatinine levels, remained stable in the majority curred in two patients who received Neoral and three of patients in both treatment groups. Four patients in the Neoral group and three patients in the Sandimmune patients who received Sandimmune. the curve (AUC) and maximum concentration (C max ) implied by the results of previous studies [20, 21] . The number of patients with at least one notable (more than 30% over baseline) increase in creatinine in this doublegroup had notably elevated creatinine levels (Ͼ30%) blind study was comparable to that seen in a recent onecompared with baseline levels for at least three months year, open-label, single-arm study [19] that employed a during the study. At study completion, five Neoral pasimilar patient monitoring scheme. A comparison of tients (4.2%) and seven Sandimmune patients (5.7%) these two conversion studies suggests that favorable outhad serum creatinine levels of more than 30% above comes for creatinine can be achieved with close monitorbaseline values (Table 4) ; of these 11 patients, 3 were ing, especially during the first four weeks after converreported as experiencing chronic graft dysfunction, all sion. in the Sandimmune group. The number of patients with Although the acute rejection and chronic graft dyscreatinine levels of more than 30% above baseline at function rates were low in both groups, chronic graft dysfunction did appear less often in patients converted to any scheduled visit throughout the study was 28 (21.2%) 
